Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Point-of-Care Testing Has Potential to Expand the Reach of NGS for CRC

January 27th 2022, 10:30pm


This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).

MRD Continues to Reliably Predict Disease Progression in CRC

January 24th 2022, 11:00pm


In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).

Understanding Real-World Trends in MRD Testing as Part of MM Management

January 18th 2022, 5:45pm


An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.

MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab

January 16th 2022, 3:00pm


An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.

Review Explores Adoption of New MRD Monitoring Method

January 13th 2022, 6:00pm


A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.

Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases

January 10th 2022, 6:07pm


Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.

MRD Indicates Relapse for Patients With Classical HL After ASCT

January 7th 2022, 10:40pm


Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT).

Ibrutinib/Venetoclax Bests Chlorambucil/Obinutuzumab for Treating CLL

December 26th 2021, 5:00pm


Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.

Top 5 Most-Read Articles in Precision Oncology for 2021

December 25th 2021, 3:00pm


Epigenetics has a role in choosing the right medicine in lung cancer, artificial intelligence can predict outcomes in a highly aggressive cancer, and more.

Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”

December 20th 2021, 4:26am


Physicians said it is in payers’ interest to use artificial intelligence to address social determinants of health, to cover tests, and to gather data. Doing so could let them stratify who needs certain screenings and diagnostic procedures and who doesn’t, which could lead to less consumption of health care.